Comparison of the efficacy of nal-IRI+5FU/LV and S-1 in patients with advanced pancreatic cancer refractory to gemcitabine and nab-paclitaxel
{{output}}
Introduction: Nanoliposomal irinotecan (nal-IRI) + 5- fluorouracil (FU)/leucovorin (LV) is the new standard second-line therapy for advanced pancreatic cancer (PC). Tegafur, gimeracil, and oteracil potassium (S-1) have been used ... ...
